Bioavailability of Orally Ingested Vitamin C (ABBA)

University of Exeter

Status: Withdrawn

Conditions: Healthy

Treatments: Dietary Supplement: Crystalline vitamin C; Dietary Supplement: Phosphatidylcholine-lipid encapsulated vitamin C

Study type: Interventional

Funder types: Other

Identifiers

NCT05183880

21-10-20-B-01

Details and patient eligibility

About

The purpose of this study is to determine if crystalline vitamin C supplementation can acutely increase skeletal muscle vitamin C concentrations and if this can be potentiated by administering vitamin C using Phosphycell™ Technology - a phosphatidylcholine-lipid encapsulation technology.

Sex: All

Ages: 18 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Body mass index (BMI) 18.5 - 30 kg/m2
• Age 18 - 40
• Non-smoker

Exclusion criteria

• Body mass index (BMI) < 18.5 or > 30 kg/m2
• Age < 18 or > 40
• Smoking
• Cardiovascular disease
• Hypertension (≥ 140/90 mmHg)
• Metabolic disease
• Medications known to affect vitamin C metabolism
• A known vitamin C deficiency
• Less than 2 hours per week of physical activity or following a structured exercise training program.
• Routine use of vitamin supplements

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

0 participants in 2 patient groups

Crystalline vitamin C supplementation

Active Comparator group

Description:

1000 mg of vitamin C ingested in crystalline form

Treatment:

Dietary Supplement: Crystalline vitamin C

Phosphatidylcholine-lipid encapsulated vitamin C supplementation

Experimental group

Description:

1000 mg of vitamin C ingested in phosphatidylcholine-lipid encapsulated form

Treatment:

Dietary Supplement: Phosphatidylcholine-lipid encapsulated vitamin C